Back to top
more

Fulcrum Therapeutics (FULC)

(Delayed Data from NSDQ)

$3.26 USD

3.26
843,623

+0.05 (1.56%)

Updated Nov 4, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -19.72% and 52.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 59.2% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics, Inc. (FULC)

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to Decline

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Fulcrum (FULC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Fulcrum (FULC) stock based on the movements in the options market lately.

Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 179% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Fulcrum Therapeutics, Inc. (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.77% and 26.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat

by Zacks Equity Research

Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.

Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal

by Zacks Equity Research

Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.

    Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

    by Zacks Equity Research

    Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

    Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

    by Zacks Equity Research

    The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.

      Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?

      by Zacks Equity Research

      The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

      Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

      Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

      Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus

      by Zacks Equity Research

      Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

      Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates

      by Zacks Equity Research

      Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.

      Fulcrum Therapeutics' (FULC) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).

      Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

      by Zacks Equity Research

      Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

      Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season

      by Zacks Equity Research

      Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

      by Zacks Equity Research

      Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.